+Compare
PCSA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
11.38M

PCSA Processa Pharmaceuticals Forecast, Technical & Fundamental Analysis

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for PCSA with price predictions
07:00 PM EST Dec 05, 2023

Momentum Indicator for PCSA turns positive, indicating new upward trend

PCSA saw its Momentum Indicator move above the 0 level on November 13, 2023. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator turned positive. In of the 45 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for PCSA just turned positive on November 14, 2023. Looking at past instances where PCSA's MACD turned positive, the stock continued to rise in of 26 cases over the following month. The odds of a continued upward trend are .

PCSA moved above its 50-day moving average on November 13, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a +4 3-day Advance, the price is estimated to grow further. Considering data from situations where PCSA advanced for three days, in of 148 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PCSA moved out of overbought territory on December 05, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator moved out of overbought territory. In of the 15 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 21 cases where PCSA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCSA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PCSA broke above its upper Bollinger Band on November 29, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.547) is normal, around the industry mean (20.710). P/E Ratio (0.000) is within average values for comparable stocks, (137.900). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (330.425).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PCSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 7%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 27%. IVBT experienced the highest price growth at 1,413%, while IBIO experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -6%. For the same stocks of the Industry, the average monthly volume growth was 2% and the average quarterly volume growth was 64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 58
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

PCSA is expected to report earnings to rise 25.00% to -10 cents per share on March 28

Processa Pharmaceuticals PCSA Stock Earnings Reports
Q4'23
Est.
$-0.10
Q3'23
Beat
by $0.02
Q2'23
Beat
by $0.05
Q1'23
Beat
by $0.05
Q4'22
Missed
by $0.49
The last earnings report on November 08 showed earnings per share of -7 cents, beating the estimate of -10 cents. With 538.90K shares outstanding, the current market capitalization sits at 11.38M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
7380 Coca Cola Drive
Phone
+1 443 776-3133
Employees
15
Web
https://www.processapharmaceuticals.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FTFT1.090.17
+17.95%
Future FinTech Group
RIVN18.380.97
+5.54%
Rivian Automotive
HMST7.340.08
+1.10%
HomeStreet
HI39.600.34
+0.87%
Hillenbrand
DWAC17.320.03
+0.17%
Digital World Acquisition Corp

PCSA and

Correlation & Price change

A.I.dvisor tells us that PCSA and SRNEQ have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCSA and SRNEQ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCSA
1D Price
Change %
PCSA100%
+1.21%
SRNEQ - PCSA
28%
Poorly correlated
+1.87%
EDIT - PCSA
28%
Poorly correlated
+1.18%
BGNE - PCSA
27%
Poorly correlated
-1.18%
VKTX - PCSA
27%
Poorly correlated
-0.69%
EDSA - PCSA
26%
Poorly correlated
+17.14%
More